Physician profile
Michael E Canfield
NPI 1124084785
$1,494.98
in general payments reported to CMS, 2019-2025
23 companies · $88.14 in 2025
The $88.14 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $207 · 2021: $348 · 2022: $327 · 2023: $108 · 2024: $188 · 2025: $88.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $171.12 | 2020-2021 | |
| Abbvie INC. | $157.09 | 2021-2023 | Vraylar |
| Sanofi-Aventis U.S. LLC | $155.95 | 2019-2022 | |
| Stryker Corporation | $151.23 | 2024-2025 | Gamma |
| Astrazeneca Pharmaceuticals Lp | $141.05 | 2020-2022 | |
| Amgen INC. | $118.72 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.82 | 2019-2024 | Jardiance |
| Abbott Laboratories | $74.89 | 2022-2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $52.53 | 2020-2022 | |
| Glaxosmithkline, LLC. | $47.95 | 2021-2022 | |
| Intuitive Surgical, INC. | $47.35 | 2021 | |
| Edwards Lifesciences Corporation | $43.75 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novo Nordisk INC | $39.74 | 2022-2024 | Ozempic |
| Astellas Pharma US INC | $29.95 | 2019-2020 | |
| Pfizer INC. | $24.77 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $22.50 | 2024 | Rexulti |
| Mylan Specialty L.P. | $21.09 | 2024 | Yupelri |
| Boston Scientific Corporation | $15.27 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.26 | 2021 | |
| Philips North America LLC | $14.15 | 2023 | |
| Lilly USA, LLC | $12.61 | 2020 | |
| Eisai INC. | $11.94 | 2021 | |
| Ibsa Pharma INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Canfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.